Background/objective: This study aims at the evaluation of the efficacy and safety of a combination therapy based on pidobenzone 4% and fractional CO2 laser or cryotherapy in the treatment of solar lentigines and the prevention of eventual posttreatment hyperchromia.

Methods: Efficacy was clinically evaluated by grading the pigmentation level with the Skin Tone Color Scale (STCS), and by grading patients' impression through a Visual Analog Scale (VAS).

Results: Our study shows that the associated treatment was safe and that it improves the therapeutic results on solar lentigines and prevents postiatrogenic hyperpigmentation compared with physical therapy alone.

Conclusion: The combination of cryotherapy and pidobenzone 4% has been found to be the most useful treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000447356DOI Listing

Publication Analysis

Top Keywords

solar lentigines
12
efficacy safety
8
treatment solar
8
safety topical
4
topical pidobenzone
4
pidobenzone adjuvant
4
treatment
4
adjuvant treatment
4
lentigines result
4
result randomized
4

Similar Publications

Background: Lentigo maligna (LM) and lentigo maligna melanoma (LMM) are the most prevalent subtypes of melanoma, primarily affecting sun-exposed areas of the face in individuals aged 65 to 80 years. LM accounts for approximately 80 % of in situ melanomas and carries a risk of progression to LMM, which constitutes 4 % to 15 % of global cutaneous melanoma cases. This report discusses the clinical challenges and management strategies for recurrent LM, with an emphasis on accurate diagnosis and surgical intervention.

View Article and Find Full Text PDF

Background: Skin pigmentation disorders may increase patients' psychological burdens. Consequently, they are increasingly attracting attention. Dermal fibroblasts have been shown to regulate pigmentation by secreting soluble factors.

View Article and Find Full Text PDF

Little is known about the anti-pigmenting effects of skin-whitening agents on solar lentigos (SLs). To characterize the anti-pigmenting effects of a newly designed derivative ascorbyl glucoside-arginine complex (AGAC) on SLs, lotions with or without 28% AGAC were applied twice daily for 24 weeks in a double-blind half-face study of 27 Japanese females with SLs. The pigmentation scores and skin colors of previously selected SLs on the right and left sides of the faces of the subjects were evaluated using a photo-scale, a color difference meter and a Mexameter.

View Article and Find Full Text PDF
Article Synopsis
  • The study examines the link between Parkinson's disease (PD) and skin cancer risk factors, looking specifically at actinic keratosis (AK), non-melanoma skin cancer (NMSC), and cutaneous malignant melanoma (CMM) among individuals with and without PD.
  • A total of 141 patients with PD and 155 controls were analyzed, revealing that CMM was more prevalent in PD patients, with risk factors like prolonged sun exposure, freckles, and solar lentigines particularly associated with skin tumours in the PD group.
  • The research indicates that while certain skin tumour risk factors exist, PD status by itself isn't independently linked to these risks, highlighting the need for regular dermatological
View Article and Find Full Text PDF

The Skin-Lightening Power of Tirbanibulin 1% Ointment.

Dermatol Ther (Heidelb)

November 2024

Department of Clinical and Experimental Medicine, Section of Dermatology, University of Messina, Messina, Italy.

Background: Tirbanibulin 1% ointment has been licensed to treat non-hyperkeratotic actinic keratosis (AK) on the face and scalp in adults. Recent evidence suggests that, besides the antineoplastic effect, tirbanibulin may also confer substantial cosmetic benefits to patients.

Methods: We report a single-center retrospective study of patients affected by solar lentigines (SLs) and AKs in the context of field cancerization treated with tirbanibulin 1% ointment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!